Engflag

Hitaxa

Quick links to important sections

Hitaxa

Hitaxa_DA

Method of action: Antiallergic, Antiexudative, Antihistamines For Systemic Use, Antipruritic, H1-Antihistamine

Treatment option: Jock Itch, Hives, Rhinitis, Hay Fever

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hitaxa

Property Description
Active ingredient Desloratadine
Form Oral Tablet, Syrup, Orally Disintegrating Tablet (ODT)
Pharmacological class Second-Generation Antihistamine
Common use Symptomatic relief of allergies
Origin Synthetic compound (Active metabolite)

Identity and Pharmacological Classification

Hitaxa is a medication classified as a second-generation antihistamine that functions as an effective antiallergic agent. The sole active ingredient, or International Nonproprietary Name (INN), in this drug is Desloratadine.

Desloratadine is a synthetic compound that is the major active metabolite of Loratadine, its related precursor. Its pharmacological action is defined as a selective peripheral H1-Receptor Antagonist, meaning it focuses on blocking histamine receptors primarily in the body’s tissues (peripheral action). This structural selectivity is the key factor that supports its profile as a reliably non-sedating agent.

Composition and Available Forms

The therapeutic purpose of Hitaxa is fully supported by its single-active ingredient composition, Desloratadine. The medicine is designed for systemic use, ensuring body-wide action after oral intake.

Hitaxa is supplied in various oral dosage forms, including the standard oral tablet, a rapidly dissolving orally disintegrating tablet (ODT), and an oral syrup formulation. The availability of the liquid and ODT forms caters to patient groups, such as children, who may require alternative methods of administration. These preparations are engineered for a consistent long-duration effect, which is clinically recognized for sustaining relief over approximately a 24-hour period.

General Purpose

The general purpose of Hitaxa is to provide symptomatic relief by serving as a potent and enduring Histamine Blocker. Its action controls general allergic distress, which might include seasonal symptoms or chronic issues like persistent itching. The primary benefit is that this medicine helps manage these symptoms effectively, while maintaining a non-sedating profile appropriate for continuation of daily activities.

Regulatory References

  1. (NIH)

What side effects are possible with Hitaxa?

Official Safety Profile and Adverse Reactions

The safety profile of Hitaxa (Desloratadine) is established through regulatory documents that classify potential adverse reactions primarily by frequency and System-Organ Class (SOC).

Frequency-Classified Effects

Adverse reactions are formally grouped according to regulatory definitions, detailing how often they have been reported:

  • Common Reactions (reported in ge1/100 to <1/10 patients): These include headache, fatigue, and dry mouth.
  • Very Rare Reactions (reported in <1/10,000 patients): Less frequent effects have been documented across multiple systems, including nervous system disorders (dizziness, somnolence, seizures), cardiac disorders (tachycardia, palpitations), and gastrointestinal disorders (nausea, vomiting, dyspepsia).
  • Frequency Not Known: This category covers reactions reported spontaneously post-marketing where the incidence rate cannot be accurately estimated, such as abnormal behavior, aggression, and QT prolongation.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling draws specific attention to rare but clinically significant events and important safety constraints:

  • Serious Adverse Reactions: The official label documents the possibility of Hypersensitivity reactions, including anaphylaxis (severe allergic reaction) and angioedema (swelling). Reports of hepatitis and seizures have also been documented in post-marketing data.
  • Population-Specific Safety: Caution is advised when using the medicine in individuals with severe renal or hepatic impairment. In the pediatric population, specific adverse events like diarrhea, fever, and insomnia have been observed more frequently in infants and toddlers. Use during pregnancy and lactation is generally not recommended as a precautionary measure.
  • Safety Restriction: The medication is contraindicated in patients with a known hypersensitivity to the active substance, loratadine, or any of the inactive ingredients.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Hitaxa

Documented Signs of Overdose

The officially documented manifestations of Desloratadine overdose typically involve the central nervous system and cardiovascular system. Presentations may include clinical signs such as somnolence (drowsiness), headache, fatigue, and tachycardia (fast heart rate). In high-exposure situations, official prescribing information mandates monitoring for the potential of serious outcomes, including QT interval prolongation and other cardiac effects.

When to Seek Immediate Medical Help

Upon any suspected overdose, official regulatory documents state that an individual must seek immediate medical attention and contact emergency services promptly. Hospital monitoring is required for clinical assessment and procedural management. Management protocols specifically include considerations for the pediatric population and patients with existing renal or hepatic impairment.

Overdose Management

No specific antidote is known for Desloratadine overdose. Treatment is strictly symptomatic and supportive, aiming to manage clinical manifestations and remove unabsorbed drug. Regulatory documents describe procedures such as the potential use of gastric lavage or administration of activated charcoal. Furthermore, continuous ECG monitoring is mandated to assess the cardiovascular status, as hemodialysis is not effective for drug removal.

Therapeutic Uses of Hitaxa

This medication is commonly used across conditions marked by increased physiological stress, primarily targeting allergic responses.

Hitaxa is applied in addressing symptomatic discomfort related to conditions characterized by periods of heightened symptoms: allergic rhinitis (both seasonal and perennial) and Chronic Idiopathic Urticaria (CIU). It helps address the cluster of upper respiratory, ocular, and dermal symptoms that interfere with daily functioning, such as frequent sneezing, watery eyes, nasal congestion, and symptoms related to physical discomfort (skin itching).

“The primary benefit is providing supports extended, day-long symptomatic relief during high-allergen exposure, which contributes to easing the overall symptom load.”

The medication is considered relevant when supportive symptom management is appropriate, especially during episodes where discomfort becomes more noticeable. This quality of symptomatic relief assists with maintaining functional stability and may assist with maintaining daytime alertness and productivity during difficult episodes.

Quick Fact: Relief for Persistent Itching
Hitaxa is applied in addressing symptoms related to physical discomfort (skin itching) and hives associated with Chronic Idiopathic Urticaria, assisting with easing the disruptive manifestations of these recurrent skin symptoms.

Regulatory References

  1. NIH MedlinePlus overview on Desloratadine

Eligibility and Restrictions for Use

Eligibility and Contraindications

Hitaxa (desloratadine) is a medicine whose use is strictly governed by regulatory labeling. Official documents define absolute exclusions, conditional use requirements, and limitations by age and physiological state.

Classification Who Must Not Use (Absolute Contraindication)
Hypersensitivity Patients with a known allergy to desloratadine, its parent compound loratadine, or any of the product's excipients.
Hereditary Condition Patients with galactose intolerance or lactose deficiencies if the formulation contains lactose.

Use Limitations and Special Populations

Eligibility is restricted for certain populations, requiring caution or dose adjustment due to pharmacokinetic considerations:

  • Organ Impairment: Patients with severe hepatic (liver) or renal (kidney) impairment require caution and a reduced dosing frequency, as the drug's clearance from the body is slower, increasing exposure.
  • Age Groups: The safety and efficacy of the tablet formulation are generally not established for children under 12 years of age. Eligibility for the oral solution form extends to certain age groups below 12 years, but use is often not recommended for infants under a specific age (e.g., 6 months to 1 year, depending on the product).
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is generally not recommended as a precautionary measure, due to desloratadine's excretion into breast milk and the unknown effects on the nursing infant.
  • Seizure History: Caution is advised for patients with a personal or family history of seizures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hitaxa, containing desloratadine, has a formally documented interaction profile based on studies reviewed by regulatory authorities such as the FDA and EMA. The profile primarily concerns pharmacokinetic interactions that modify drug exposure, though these changes are generally not classified as clinically significant in terms of safety.

Documented Pharmacokinetic Interactions

Co-administration with certain medicinal products has been shown to increase the plasma concentrations (Cmax and AUC) of desloratadine and its active metabolite. These interacting substances, often classified as inhibitors of drug metabolism or transport, include:

  • Ketoconazole (an antifungal)
  • Erythromycin and Azithromycin (macrolide antibiotics)
  • Cimetidine (an H2-receptor antagonist)
  • Fluoxetine (an SSRI)

Despite the observed increases in drug exposure, official regulatory documents state that these interactions did not result in clinically relevant changes in the safety profile, including assessment of the corrected QT interval.

Other Documented Interactions

Interaction Type Official Regulatory Statement
Pharmacodynamic Effects (Alcohol) Desloratadine did not potentiate the performance-impairing effects of alcohol in formal clinical pharmacology trials.
Food Administration Taking the drug with or without a meal does not affect its bioavailability, and no mandatory timing separation is required.
Population-Specific Note Increased drug exposure is officially documented in patients with hepatic impairment and renal impairment due to slower drug clearance.

No medicinal products are formally listed as contraindicated for co-administration with single-ingredient desloratadine in primary US or EU labels.

Mechanism of Action

How Hitaxa Works

Hitaxa exerts its effect primarily through two distinct mechanistic domains. The drug acts as a highly selective antagonist for the Histamine H1-receptor, binding to the receptor site and blocking the natural signaling molecule histamine from causing activation. This mechanistic blockade results in the reduction of histamine-induced increases in vascular permeability and a subsequent decreased extravasation of fluid from blood vessels, alongside reduced activation of sensory nerve endings.

Additionally, the mechanism involves an influence on specific immune cells, such as mast cells and basophils. This activity promotes the stabilization of these cells and functions as an inhibitor against the release of pro-inflammatory mediators. The drug is structurally characterized by its low penetration across the blood-brain barrier, which concentrates its effect on peripheral biological targets. This results in the adjustment of physiological responses in the peripheral tissues, with limited interaction with central nervous system function.

Dosage and Administration Information

Instruction Map: How to use Hitaxa — Administration Guidelines

This map outlines the instructions for the use of Desloratadine.

Instruction Detail
Route of administration Oral use (PO) for all formulations (tablet, ODT, oral solution).
Dosing schedule Adults and Adolescents (≥ 12 years): 5 mg once daily. Pediatric dosing is lower and age-specific, using strengths like 1 mg or 1.25 mg for younger children.
Timing in relation to meals May be taken with or without food, as there is no necessary timing restriction relative to meals.
Preparation requirements The oral solution must be measured accurately using a calibrated measuring device. ODTs should not be removed from the blister until immediate administration.
Population-specific rules Adults with renal or hepatic impairment are instructed to use a modified regimen of 5 mg every other day as an initial dose.
Missed-dose rules If a dose is missed, it should be taken promptly; however, instructions prohibit taking two doses concurrently.
Classification Detail
Administration method type Oral.
Frequency pattern Once daily (qDay) is the standardized schedule across all approved indications.
Use-context constraints Duration is guided by the persistence of symptoms: either intermittent (use stops when symptoms resolve) or continuous (for persistent chronic conditions).

Resulting procedural structure

  • The appropriate dosage strength must be determined based on age-group rules.
  • The dose is administered once daily, maintaining consistency in timing.
  • The dose is taken with or without food.

Connection to the overall use protocol: The instructions establish a once-daily oral intake protocol intended for systemic distribution, supporting a full 24-hour effect. The instructions define a standard 5 mg dose for adults and require specific administration steps for the oral solution and ODT forms. The protocol also integrates dosing adjustments for patients with specific organ impairment.

Recent Clinical Evidence

Hitaxa: Recent Clinical Evidence

Hitaxa (desloratadine) has been the subject of numerous clinical studies, including large-scale randomized, double-blind, placebo-controlled trials and post-marketing surveillance reports. These studies primarily focus on its use for conditions associated with histamine release, specifically Allergic Rhinitis (AR) and Chronic Idiopathic Urticaria (CIU).

Efficacy in Allergic Rhinitis

Clinical trials involving patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) consistently show that desloratadine use is associated with a reduction in the total symptom scores compared to placebo. Relief was observed for key symptoms, including sneezing, runny nose (rhinorrhea), nasal itching, and eye symptoms. Research has also explored the effect of desloratadine on nasal congestion, with studies suggesting improvement in this symptom in patients with AR.

Efficacy in Chronic Urticaria

In studies of patients with chronic idiopathic urticaria (CIU), desloratadine use was associated with improvements in key measures of disease activity. Specifically, randomized trials demonstrated that use of the medication reduced the severity of pruritus (itching), the number of wheals (hives), and the size of the largest wheal. Furthermore, treatment was associated with self-reported improvements in sleep interference and the performance of daily activities for many participants.

Safety and Tolerability Profile

Evidence from clinical trials and post-marketing surveillance involving a large number of patients suggests that desloratadine is generally well-tolerated. The incidence of reported adverse events, such as fatigue, headache, and dry mouth, has been comparable between the desloratadine and placebo groups in many controlled studies. Desloratadine is classified as a non-sedating antihistamine; research investigating its effect on central nervous system function, including psychomotor performance and cognitive measures, has found minimal clinically significant impact at the recommended dose.

Frequently Asked Questions (FAQ)

Common questions about Hitaxa (FAQ)

Q: What kind of allergies is Hitaxa prescribed to treat?

Official regulatory documents indicate that this medication is approved for the relief of symptoms related to allergic rhinitis, which includes both seasonal and year-round (perennial) allergies. It is also indicated for the treatment of symptoms associated with chronic idiopathic urticaria, commonly known as persistent hives.

Q: What should I do if I forget or miss a dose of Hitaxa?

Official product information advises that a missed dose may be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, regulatory information indicates that the missed dose should be skipped, and the patient should simply take the next one as planned. It is specifically noted that two doses should not be taken at the same time to compensate for a missed dose.

Q: How long does it take for Hitaxa to start working after I take it?

Studies and official information indicate that the anti-allergic effect (antihistaminic effects) of the medication can begin to appear within one hour after taking a single dose. Patients may start to notice an overall improvement in their symptoms as quickly as one day after beginning their therapy.

Q: How do I know if the Hitaxa tablets have expired?

According to general regulatory requirements for marketed drugs, the product’s expiration date is required to be clearly marked on the outer packaging, such as the bottle or the box label. This date is usually displayed in a clear format (e.g., Month/Year) and indicates the last day the manufacturer guarantees the product's full potency and safety.

How should Hitaxa be stored and disposed of?

The storage and disposal of Hitaxa (desloratadine) must strictly follow the official instructions provided in regulatory labeling to ensure product quality and environmental safety.

Official Storage Requirements

Hitaxa tablets and oral solution must be stored at controlled room temperature or at a temperature not exceeding 30°C (86°F). The medicine must be kept in the original package to protect from moisture and must also be shielded from excess heat and freezing (particularly the syrup formulation). If supplied in a container, certain products require use within 3 months after first opening to maintain stability.

Handling and Disposal

It is a mandatory safety instruction to keep this medicine out of the sight and reach of children. When discarding, unused or expired Hitaxa must not be thrown away via wastewater or household waste. Patients are directed to dispose of the product according to local regulations or return it to a designated pharmacy or collection scheme.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPoland

Equivalent of Hitaxa found in:

A-Z Index: